Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

DomaCom IPO – CEO interview

Bell Direct
July 21, 2016

How to Trade ETFs: Peter Harper

Bell Direct
July 21, 2016

Market Update 20 July

Julia Lee
July 20, 2016

Technical Insights – Trailing Stops

Bell Direct
July 18, 2016

Market Update 18 July

Julia Lee
July 18, 2016

Market Update 15 July

Julia Lee
July 15, 2016

Market Update 14 July

Julia Lee
July 14, 2016

Market Update 13 July

Julia Lee
July 13, 2016